Keywords: Brentuximab Vedotin; Chronic graft-versus-host disease; Brentuximab vedotin; Allogeneic hematopoietic cell transplantation; Phase I study;
مقالات ISI Brentuximab Vedotin (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Hodgkin lymphoma; Pulmonary infiltration;
Keywords: Brentuximab Vedotin; Brentuximab vedotin; checkpoint inhibitors; nivolumab; pembrolizumab; transplant;
Keywords: Brentuximab Vedotin; Anaplastic large-cell lymphoma; Treatment; Brentuximab vedotin; Stem cell transplant;
Keywords: Brentuximab Vedotin; Hodgkin lymphoma; Relapse; High-dose chemotherapy; Autologous stem cell transplant; Brentuximab vedotin
Keywords: Brentuximab Vedotin; Sphere-on-sphere particles; Fractal column; Column efficiency; Monoclonal antibody; Rituximab; Brentuximab vedotin;
Keywords: Brentuximab Vedotin; chłoniak Hodgkina; chemiooporność; wznowa; leczenie II linii; brentuksymab wedotinuHodgkin's lymphoma; Chemoresistance; Relapse; Second line treatment; Brentuximab vedotin
Keywords: Brentuximab Vedotin; Autologous hematopoietic transplantation; Salvage; Hodgkin lymphoma; Brentuximab vedotin
Keywords: Brentuximab Vedotin; Bendamustine; Brentuximab vedotin; Hodgkin's lymphoma; Refractory; Relapsed
Keywords: Brentuximab Vedotin; Anaplastic large cell lymphoma; Antibody–drug conjugate; Brentuximab vedotin; CD30; Hodgkin lymphoma; Named Patient Program
Keywords: Brentuximab Vedotin; Allogeneic transplantation; Reduced-intensity; Hodgkin lymphoma; Brentuximab vedotin
Keywords: Brentuximab Vedotin; Hodgkin lymphoma; Relapsed disease; Targeted therapies; Brentuximab vedotin;
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Checkpoint inhibitors; Haploidentical; Nivolumab; Pembrolizumab;
Le lymphome de Hodgkin : stratégies thérapeutiques actuelles et futures
Keywords: Brentuximab Vedotin; Lymphome de Hodgkin; Radiothérapie involved-site; Brentuximab vedotin; Anti-PD1; Hodgkin lymphoma; Radiotherapy involved-site; Brentuximab vedotin; Anti-PD1 antibody;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33,
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Daratumumab; Gemtuzumab ozogamicin; Infection; Inotuzumab ozogamicin; Lucatumumab; Mogamulizumab; Moxetumomab pasudotox;
SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Hodgkin lymphoma; Initial therapy; PD-1 inhibitors; PET-adapted therapy;
The unique biology and treatment of primary mediastinal B-cell lymphoma
Keywords: Brentuximab Vedotin; Anti-PD-1; CD30; Brentuximab vedotin; CHOP; DA-EPOCH; MACOP-B; PD-1; JAK/STAT; Primary mediastinal large B-Cell lymphoma; Pembrolizumab; Radiotherapy; Rituximab; Ruxolitinib; VACOP-B;
Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Clinical trials; Inotuzumab ozogamicin; Polatuzumab vedotin; Site-specific conjugation;
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: Brentuximab Vedotin; ARGX-110; Brentuximab vedotin; Bortezomib; Copanlisib; cutaneous T-cell lymphoma; Forodesine; Gemcitabine; HDAC inhibitors; Ipilimumab; IPH4102; Mogamulizumab; Nivolumab; NM-IL-12; Panobinostat; Pegylated liposomal doxorubicin; Pentostatin; Pralatrexate;
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Relapse or refractory NHL; CD30;
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: Brentuximab Vedotin; Alisertib; ARGX-110; Belinostat; Bendamustine; Brentuximab vedotin; Copanlisib; Duvelisib; Gemcitabine; Lenalidomide; Mogamulizumab; Peripheral T-cell lymphoma; Pralatrexate; Refractory; Relapsed; Romidepsin; Selinexor;
Separation of antibody drug conjugate species by RPLC: A generic method development approach
Keywords: Brentuximab Vedotin; Retention modelling; Antibody drug conjugate; Brentuximab vedotin; Method development; DryLab; Reversed phase liquid chromatography;
Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature
Keywords: Brentuximab Vedotin; CD30; Solid tumor; Non-hematopoetic; Non-lymphomatous; Ki-1; Brentuximab vedotin; Antibody-drug-conjugate;
Actualités thérapeutiques dans le lymphome de Hodgkin
Keywords: Brentuximab Vedotin; Lymphome de Hodgkin; TEP; Inhibiteurs checkpoint immunitaire; Brentuximab vedotin; Hodgkin Lymphoma; PET-CT; Immunological checkpoint inhibitor; Brentuximab vedotin;
Fatal pancreatitis occurred in a patient with refractory CD30+ anaplastic large cell lymphoma after brentuximab vedotin treatment
Keywords: Brentuximab Vedotin; Pancreatitis; Anti-CD30; Brentuximab vedotin; Anaplastic large cell lymphoma;
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
Keywords: Brentuximab Vedotin; AE; Adverse Event; α-MSH; alpha-Melanocyte Stimulating Hormone; ADC; Antibody-Drug Conjugate; ASPS; Alveolar Soft Part Sarcoma; ASPSCR1; Alveolar Soft Part Sarcoma Chromosome Region Candidate 1; BMP-2; Bone Morphogenetic Protein-2; BRK; Breast Tumor Kina
Angioimmunoblastic T-Cell Lymphoma
Keywords: Brentuximab Vedotin; Angioimmunoblastic T-cell lymphoma; Autologous stem cell transplantation; Brentuximab vedotin; CHOP; DNMT3A; Follicular T-helper; IDH2; Lenalidomide;
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Keywords: Brentuximab Vedotin; Hodgkin lymphoma; Allogeneic stem cell transplantation; Bone marrow transplantation; Brentuximab vedotin;
ReviewBrentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program
Keywords: Brentuximab Vedotin; Antibody-drug conjugate; Brentuximab vedotin; CD30; Hodgkin lymphoma; Named patient program;
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
Keywords: Brentuximab Vedotin; 2-CdA; 2-chlorodeoxyadenosine; ADC; antibody-drug conjugate; ALCL; anaplastic large cell lymphoma; ANC; absolute neutrophil count; ASM; aggressive systemic mastocytosis; BM; bone marrow; CT; computed tomography; ECNM; European Competence Network on Mastoc
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
Keywords: Brentuximab Vedotin; Embryonal carcinoma; Salvage therapy; Testicular cancer; CD30; Brentuximab vedotin;
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
Keywords: Brentuximab Vedotin; Adult T-cell leukemia/lymphoma; Anaplastic large cell lymphoma; Angioimmunoblastic T-cell lymphoma; Belinostat; Brentuximab vedotin; Peripheral T-cell lymphoma; Pralatrexate; Romidepsin;
Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma
Keywords: Brentuximab Vedotin; Anti-PD-1; Brentuximab vedotin; Fluorodeoxyglucose positron emission tomography; Methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin, prednisone; Primary mediastinal B-cell lymphoma; Radiotherapy; Rituximab; Ruxolitinib;
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas
Keywords: Brentuximab Vedotin; Bexarotene; Brentuximab vedotin; Cutaneous T-cell lymphoma; Mycosis fungoides; Romidepsin; Sézary syndrome; Vorinostat;
Rola przeciwciał monoklonalnych anty CD30 i anty PD-1 w terapii nawrotowego/opornego chłoniaka Hodgkina
Keywords: Brentuximab Vedotin; chłoniak Hodgkina; brentuksimab vedotin; nivolumab; pembrolizumabHodgkin lymphoma; Brentuximab vedotin; Nivolumab; Pembrolizumab
Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper
Keywords: Brentuximab Vedotin; Brentuximab vedotin; Consensus project; Guidelines; Hodgkin lymphoma; Systemic anaplastic large-cell lymphoma
New drugs and targeted treatments in Hodgkin's lymphoma
Keywords: Brentuximab Vedotin; Target treatments; Hodgkin's lymphoma; Brentuximab vedotin; Deacetylase inhibitors; Bendamustine; Lenalidomide; m-TOR inhibitors;
Treatment strategies for peripheral T-cell lymphomas
Keywords: Brentuximab Vedotin; peripheral T cell lymphoma; angioimmunoblastic T-cell lymphoma; HTLV-1 associated T cell lymphoma; enteropathy associated T-cell lymphoma; panniculitis-like T-cell lymphoma; monoclonal antibodies; denileukin diftitox; brentuximab vedotin; pralatrexate; hi
Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms
Keywords: Brentuximab Vedotin; Anaplastic large-cell lymphoma; Brentuximab vedotin; Classic Hodgkin lymphoma; Internalization kinetics; SGN-35;
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
Keywords: Brentuximab Vedotin; Reed Sternberg; Brentuximab vedotin; SGN-35; Panobinostat; HADC; Everolimus; mTOR; Rituximab